Answers are grounded in this paper and cite their sources.
Randomized trial evaluates efficacy of cadonilimab combined with GC in unresectable biliary tract cancer, suggesting potential for improved outcomes.
e16177 Background: PD-(L)1 inhibitor combined with GC is an established first-line treatment for unresectable BTC. However, most pts still experience disease progression, and no universally accepted second-line regimen exists. Surgery remains the only potentially curative option. Cadonilimab is a tetrameric bispecific antibody both targeting PD-1 and CTLA-4. This study evaluates the efficacy and safety of AK104 plus GC as a conversion therapy for unresectable or systemic treatment-failed BTC pts. Methods: This ongoing single-center phase II trial enrolls two cohorts. Cohort A (treatment-naïve, unresectable) received up to 8 cycles of AK104 (10mg/kg) + GC (Q3W), with imaging every two cycles to assess resectability. Pts converted to resectable undergo surgery followed by AK104 or combined with GC (combination cycles at investigator’s discretion); unresectable pts switch to AK104 monotherapy—all until PD. Primary endpoints were R0 resection rate and OS. Cohort B (prior systemic-therapy failed) received AK104+GC (investigator-determined cycles) followed by AK104 maintenance, with OS as the primary endpoint. Secondary endpoints for both cohorts were PFS, ORR, DCR and safety. Results: As of Nov 2025, 31 pts were enrolled (14 treatment-naïve, 17 systemic therapy-failed), all with ECOG PS 1. Baseline characteristics for treatment-naïve pts: ICC 28.6%, ECC 42.8%, GBC 28.6%, stage III–IV 85.7%; for systemic therapy failed pts: ICC 11.8%, ECC 41.1%, GBC 47.1%, stage III-IV 94.1%, with 94.1% having received prior ICIs plus chemotherapy. Median maximum tumor diameter was ~32 mm in both cohorts. Among 22 evaluable pts (11 per cohort), the overall ORR was 36.4% and mPFS was 4.8 mo (95% CI 2.6-NE); mOS was not reached at a median follow-up of 5.5 mo (95%CI 4.3-11.2). In treatment-naïve unresectable pts, ORR was 54.5% with an R0 conversion rate of 18.2% (2/11), and median PFS and OS were not reached. In systemic therapy-failed pts, ORR was 18.2%, mPFS was 3.3 mo (95% CI 2.0-9.7), and mOS was 6.9 mo (95% CI 4.1-NE). Grade ≥3 TRAEs occurred in 48.4% (15/31) pts. The most common any grade TRAEs were decreased lymphocyte count (55%), decreased white blood cell count (42%), and anemia (42%). No treatment-related deaths occurred. Conclusions: Cadonilimab combined with GC showed promising anti-tumor activity and manageable safety in both unresectable and systemic treatment-failed BTC pts. Longer follow up is required to further evaluate the efficacy and safety. Clinical trial information: MR-31-24-050538. Efficacy outcomes. Evaluable pts n, (%) treatment-naïven=11 systemic therapy-failed n=11 Alln=22 ORR 6(54.5) 2(18.2) 8(36.4) PR 6(54.5) 2(18.2) 8(36.4) SD 3(27.3) 3(27.3) 6(27.3) PD 2(18.2) 6(54.5) 8(36.4) DCR 9(81.8) 5(45.5) 14(63.6) R0 conversion rate 2(18.2) / / mPFS, mo (95%CI range) NR 3.3 (95% CI 2.0–9.7) 4.8 (95% CI 2.6–NE) mOS, mo (95%CI range) NR 6.9 (95% CI 4.1–NE) NR
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: